South Korean firm Celltrion Healthcare (KRX: 068270) has called on the UK’s public healthcare provider, the National Health Service (NHS), to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA).
The firm notes that, while the percentage of patients who are treated with an anti-TNF is 24% or higher in countries such as Italy and France, in the UK the figure is just 15%.
This is due to the fact that, in the UK, a patient must have a more severe level of the disease before being considered for treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze